Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. At Biohaven, we are researching new targets to treat neuropathic pain, including TRPM3 and Kv7 ion channels. Biohaven expects to submit an IND application to the FDA for BHV-2100, our lead TRPM3 antagonist, in the second half of 2023.